BCTXL

BriaCell Therapeutics Corp. Warrant expiring 2031

BCTXL

1.00 USD

+0.20

25%

1 day

25%

5 days

53.85%

1 month

7.53%

3 months

7.53%

6 months

7.53%

Year to date

7.53%

1 year

7.53%

5 years

7.53%

10 years

7.53%

About: BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Employees: 4

Healthcare Drug Manufacturers - General

–

Funds holding %

of 7,539 funds

Explore Fund Trends

–

Analysts bullish %

See Analyst Outlook

–

Positive news %

Check Journalist POV